Hiroki Ishikawa

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

Hiromitsu Kumada, Yoshiyuki Suzuki, Kenji Ikeda et al. · Hepatology · 2014 · 538 citations · Full text

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders

Kazuaki Chayama, Shoichi Takahashi, Joji Toyota et al. · Hepatology · 2011 · 335 citations

Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection

Kazuyuki Ohata, Keisuke Hamasaki, Kan Toriyama et al. · Cancer · 2003 · 317 citations · Full text

Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options

Yoshiyuki Suzuki, Kenji Ikeda, Fumitaka Suzuki et al. · Journal of Hepatology · 2012 · 235 citations

Limited Treatment Options, Viral Hepatitis, Hcv Genotype 1B +9

Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease

Yoshio Sumida, Toshiaki Nakashima, Takaharu Yoh et al. · Journal of Hepatology · 2002 · 213 citations · Full text

Inflammation, Metabolic Syndrome, Metabolic Associated Steatohepatitis +10